Summit Therapeutics, Inc. (SMMT)
17.69
-0.94
(-5.02%)
USD |
NASDAQ |
Dec 09, 12:01
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.17B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.46% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 68.50 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0282 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 95.40% |
Profile
| Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL. |
| URL | http://www.smmttx.com |
| Investor Relations URL | https://www.smmttx.com/investor-information/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Oct. 20, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL. |
| URL | http://www.smmttx.com |
| Investor Relations URL | https://www.smmttx.com/investor-information/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Oct. 20, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |